In December of 2024, I identified OraSure Technologies (NASDAQ: OSUR ) as undervalued with relatively low-risk given its robust balance sheet. Since then, OSUR has gotten even cheaper amidst increased market scrutiny of the healthcare sector. The** Comments are my own (not my firm's) and no one else's**I worked for many years at an investment firm where I invested across public and private market opportunities. I underwrote fund managers, as well as individual securities. I left the firm to pursue an MBA fr ...

OraSure Technologies (OSUR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -20%. A quarter ago, it was expected that this diagnostic test maker would post a loss of $0.02 per share when it actually produced a loss of $0.06, delivering a surprise of -200%. Over the last four quarters, th ...

OraSure (OSUR) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Company Participants Jason Plagman - VP - Investor RelationsCarrie Manner - President & Chief Executive OfficerKenneth McGrath - Chief Financial OfficerNoah Lewis - Equity Research Associate Conference Call Participants None - Analyst Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies, Inc. Twenty twenty five First Quarter Earnings Conference Call. At this time, all participants are in a listen only mode. After ...

OraSure (OSUR) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the OraSure Technologies, Inc. Twenty twenty five First Quarter Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Jason Plagman, Vice President of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ . Commission File Number 001-16537 ____ ...

EXHIBIT 99.1 Investor Contact: Media Contact: Jason Plagman Amy Koch investorinfo@orasure.com media@orasure.com VP, Investor Relations Director, Corporate Communications OraSure Announces First Quarter 2025 Financial Results BETHLEHEM, PA, May 7, 2025 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2025. "Our Q1 results were consistent ...

"Our Q1 results were consistent with our expectations. Our customers continue to demonstrate their preference for our differentiated products in delivering on their important health objectives, even while uncertainty remains elevated related to government funding sources for some segments," said OraSure President and CEO Carrie Eglinton Manner. "We are making good progress in advancing our innovation roadmap, including multiple new product milestones planned in 2025, and OTI is positioned to deliver acceler ...

文章核心观点 - 回顾2024年11月对OraSure Technologies的分析，当时公司股价约为每股4美元，目前已跌至每股3美元以下 [1] 分析师背景 - 作为价值投资者，专注于寻找罕见且优质的买入机会，采用净流动资产价值分析和超保守现金流折现计算进行深度价值投资 [1] - 职业为Charter Communications的IT项目经理，拥有计算机科学学士学位，投资主要集中在科技领域 [1] - 作为Seeking Alpha撰稿人，目标是总结自身投资、帮助他人学习价值投资过程并与志同道合的资金分配者展开交流合作 [1]

文章核心观点 OraSure Technologies公司将于2025年5月7日下午5点（美国东部时间）举行财报电话会议，公布2025年第一季度财务结果和业务进展 [1] 会议安排 - 电话会议网络直播将在OraSure公司网站投资者关系页面进行，需提前10分钟点击链接注册并获取访问权限，会议结束后将在网站存档约一年 [2] - 想在会议中提问的参与者需通过指定链接预注册，注册后将通过电子邮件收到访问详情 [3] 公司介绍 - OraSure通过可操作的洞察改变健康，推动人们与医疗保健的连接，凭借创新的简易测试和样本管理解决方案改善医疗保健的可及性、质量和价值 [3] - 公司及其子公司是快速诊断测试和样本采集及稳定设备的开发、制造和分销领域的领导者，产品全球销售 [3] 联系方式 - 投资者联系人为Jason Plagman，邮箱为investorinfo@orasure.com [3] - 媒体联系人为Amy Koch，邮箱为media@orasure.com [3]

文章核心观点 - 奥拉苏尔技术公司董事会授权未来24个月内回购至多4000万美元普通股，资金来自手头现金 [1] 公司动态 - 公司董事会授权未来24个月内回购至多4000万美元普通股，资金来自手头现金 [1] - 公司可通过多种符合州和联邦证券法的方法回购股份，回购数量和时间由管理层决定，且公司可自行决定随时修改、暂停或终止该计划，无需提前通知 [2] 公司介绍 - 奥拉苏尔技术公司通过可操作的洞察改变健康，推动人们在任何地方与医疗保健建立联系，凭借便捷测试和样本管理解决方案的创新改善医疗保健的可及性、质量和价值 [3] - 公司及其全资子公司是快速诊断测试以及样本收集和稳定设备的开发、制造和分销领域的领导者，产品全球销售 [3] 联系方式 - 投资者联系：副总裁Jason Plagman，邮箱investorinfo@orasure.com [5] - 媒体联系：企业传播总监Amy Koch，邮箱media@orasure.com [5]